#United States #New York #class action lawsuit #Faruqi & Faruqi #Baxter International

Baxter International's Legal Troubles

In recent weeks, Baxter International Inc. has come under scrutiny as questions arise regarding the safety of its Novum LVP medical device. Investors who have suffered losses from the company's stock due to these issues are being urged to take action. Faruqi & Faruqi, LLP, a prominent national securities law firm, is leading an investigation into potential claims on behalf of Baxter’s investors.

Context of the Investigation

Baxter, which trades on the NYSE under the symbol BAX, is facing legal challenges stemming from allegations that the company and its executives made misleading statements regarding the Novum LVP system. This system has reportedly suffered from significant defects, leading to serious malfunctions that could potentially harm patients. Investors who experienced losses in Baxter stocks between February 23, 2022, and July 30, 2025, are encouraged to reach out to Faruqi & Faruqi to discuss their legal rights and options.

Details of the Claims

According to the complaints being filed, Baxter is accused of failing to adequately report on the systemic issues with the Novum LVP. Allegations include that Baxter was aware of malfunctions causing underinfusion, overinfusion, and in some cases, complete failure to deliver fluids. Such defects pose severe risks, including the potential for seriously compromising patient health and safety.

Stock Market Impact

The consequences of these revelations have already begun to affect Baxter's stock price negatively. On July 31, 2025, following the announcement that Baxter would be pausing shipments and installations of the Novum LVP system, the company's shares plummeted by around 22.4%, closing at $21.76. This incident has prompted increased urgency for investors to act, as the December 15, 2025, deadline for submitting leads in the federal class action lawsuit is fast approaching.

Your Rights as an Investor

Under the law, a lead plaintiff represents the interests of all class members in a securities class action. Investors have options - they can choose to take a more active role by stepping forward as lead plaintiff or remain an absent member of the class. Regardless of the choice, any recovery they may receive would not be affected.

Faruqi & Faruqi is also seeking information from current and former employees, whistleblowers, and anyone who may have insights into Baxter’s practices, which could bolster the case against the company. Those interested in participating or sharing information are directed to contact Partner Josh Wilson directly at either of the provided numbers.

Conclusion

As the legal framework develops, Baxter’s investors may find it critically important to stay informed about the implications of the ongoing investigations. Participation in the class action may not only be a way to make their voices heard but also a potential avenue for financial recovery. For more information on these developments and steps to take as an investor, visit www.faruqilaw.com/BAX or contact Faruqi & Faruqi directly.

In summary, the situation at Baxter International serves as a sobering reminder to investors. Vigilance, awareness, and timely action can be essential in navigating the legal and financial landscapes surrounding corporate governance and accountability.